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Abstract 
BACKGROUND: Fresh frozen plasma (FFP) is widely used in critically ill patients to correct the deficiency of 
coagulation factors or increased INR.  
AIM: In the present study we aimed to evaluate the outcome of the freshly frozen plasma use as prophylaxis in 
ICU patients before an invasive procedure. 
METHODS: The study was conducted at Central Anaesthesiology and Intensive Care Service UHCT “Mother 
Theresa”, Tirana. 136 patients were enrolled with coagulopathy with no bleeding before the invasive procedure, 
from June 2016 to December 2016. A group of 75 patients underwent a median volume of 12.5 ml/kg FFP given, 
and 61 had no transfusion. Data were collected on demographics, the severity of illness measured by APACHE III 
scores, INR, medication use, hemodynamic data. 
RESULTS: From 136 patients with coagulopathy with no bleeding who underwent planned invasive interventions, 
75 [55%] received FFP, vs 61 [45%] p = 0.04 who did not receive. Overall, the median FFP dose was 12.5 ml kg-
1. Median INR level in FFP and non-FFP groups was respectively 3.1 (1.9-4.8) and 3.5 (1.8-5.2). INR was 
corrected in 24 of 75 (32%) of those who received a transfusion. The frequency of minor bleeding episodes was 
9.3% in transfused patients vs 4.9% in the non-transfused group. Patients who developed an onset of acute lung 
injury were more frequent in the FFP group. No allergic transfusion complications were observed. Also, the 
median length of hospital stay [LOS] was 3.05 days vs 2.91 days and mortality rate 8.2% vs 6.5% with no 
significant difference between two groups. 
CONCLUSIONS: Freshly frozen plasma transfusions are often unnecessarily administered during an inadequate 
correction of the deficiencies of coagulation factors. When comparing a liberal FFP transfusion strategy vs 
restrictive other clinical trials are required to asses which one is the best to adopt in intensive care settings. 
 
 
 
 
 
 
 
 
 
Introduction 
 
The use of FFP has significantly increased in 
the past 10 years, and its usage continues to 
increase. There are certain situations where FFP is 
indicated, such as in patients with coagulopathy 
resulting from DIC who are undergoing invasive 
procedures or having active bleed, in patients with 
liver failure with active bleed and patients with 
thrombotic thrombocytopenic purpura (TTP) [1]. 
Fresh frozen plasma is widely used in ICU 
patients and prescribed for the treatment of bleeding 
or the prevention of bleeding in critically ill patients. 
However, there are few detailed, prospective, 
descriptive data from large studies describing these 
patterns of use in the critically ill and clinical evidence 
to help aid the critical care clinician make decisions on 
whether to transfuse or not is at present limited [2] [3].  
It is now usually used in cases of excessive 
bleeding or to prevent bleeding in those patients with 
abnormal coagulation tests that are undergoing an 
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invasive procedure. Its use has been extended to 
patients with a coagulopathy but who are not bleeding 
(for instance, in the ICU) [4]. 
In the last decade, use of FFP has expanded 
to include prophylactic administration of FFP. 
However, there are concerns about the efficacy of 
FFP to prevent bleeding. Evidence from randomised 
controlled trials that support FFP transfusion to correct 
coagulopathy before an invasive procedure is limited, 
including commonly performed procedures on the 
ICU, such as insertion of a central venous catheter, a 
chest drain or a percutaneous tracheotomy [5]. 
Moreover, retrospective studies suggest that the risk 
of bleeding after an invasive procedure is low and 
relevant bleeding requiring blood transfusion or 
intervention is less than 1% [6]. 
Furthermore, FFP contains antibodies 
capable of causing complications like hemolytic 
reactions and transfusion-related acute lung injury. It 
is also capable of transmitting viruses like human 
immunodeficiency virus, hepatitis B virus, and C virus 
[7]. Hence, the use of FFP is not without potential 
danger, and it should be used only if indicated.  
Most clinical uses of FFP, currently 
recommended by practice guidelines, are not 
supported by evidence from randomised trials. In 
particular, there is little evidence for the effectiveness 
of the prophylactic use of FFP [5]. 
 
 
Material and Methods 
 
This prospective observational study was 
conducted at Central Anaesthesiology and Intensive 
Care Service UHCT “Mother Theresa”, Tirana. Data 
were collected prospectively from 136 patients 
admitted to ICU with coagulopathy with prolonged 
International Normalized Ratio (INR) ≥ 1.5 at any time 
during their ICU stay; with no bleeding before the 
invasive procedure, from June 2016 to December 
2016.  
Inclusion criteria were: > 18 years old, 
prolonged International Normalized Ratio (INR) ≥ 1.5, 
and undergoing any invasive procedure.  
Exclusion criteria: thrombocytopenia <5 x 
10
3
μ/L, hemodynamic instability, active bleeding; 
patients on warfarin, heparin and other anticoagulants 
treatment. All patients are carefully evaluated for next 
24 hours from admission time, and all data were 
collected on demographics, the severity of illness 
measured by APACHE III scores, INR, medication 
use, hemodynamic data. The level of INR prompting 
FFP transfusion was recorded for patients who 
received FFP transfusion and the highest level of INR 
during their ICU stay, compared with patients that 
were not transfused with FFP. 
Repeated post-invasive procedure 
measurements were made after 1 and 24 hours. The 
outcomes measured are relevant bleeding and 
correction of International Normalized Ratio. Standard 
tests were used for comparisons of proportions and 
means. Acute lung injury was recorded if it developed 
within 72 hrs after FFP administration or within 72 hrs 
after the highest recorded INR value in patients who 
did not receive FFP. Independent variables, such as 
warfarin or heparin anticoagulation, INR level, RBC 
transfusion and invasive procedure were used in the 
final model. Categorical outcome variables were 
compared between two groups based on the chi-
square test. Clinical outcomes including hospital 
mortality and ICU length of stay among survivors were 
also recorded. Continuous outcome variables were 
compared using Student’s t-test. To determine the 
clinical characteristics associated with FFP 
transfusion, logistic regression analysis was 
performed with FFP transfusion as the dependent 
variable. All P values are one-tailed, and the result is 
significant at p ≤ 0.05. 
 
 
Results 
 
From a total of 518 patients that were 
admitted to the ICU during the study period, 189 
patients (36.5%) met our criteria. A total of 53 patients 
with active bleeding were excluded. In a total of 136 
patients with elevated INR, coagulopathy and no 
bleeding, 75 (55%) received FFP vs. 61 [45%] who 
had no transfusion. Median INR levels in FFP and non 
FFP groups was respectively 3.1 (1.9-4.8) and 3.5 
(1.8-5.2). INR was corrected in 24 of 75 (32%) of 
those who received transfusion. 
Transfusion was administered before an 
invasive intervention was required. There was no 
difference in age, sex, median APACHE III scores, or 
INR level between the FFP and non-FFP groups. It 
was a difference seen in patients who developed an 
onset of acute lung injury which was more frequent in 
the FFP group: 12% vs. 3% in non-transfused group. 
No allergic transfusion complications were observed. 
In addition, the median length of hospital stay 
[LOS] was 3.05 days vs. 2.91 days and mortality rate 
8.2% vs. 6.5% p = 0.707 with no significant difference 
between two groups.  
 
 
Discussion  
 
In our study, we saw that exists a significant 
variation in the use of FFP in critically ill patients with 
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coagulopathy but with no active bleeding. New 
bleeding episodes were very rare and did not differ 
between the groups that took FFP transfusions, and 
those who did not and the use of FFP was associated 
with the development of acute lung injury. 
In our findings, in only 24 of our 75 (32%) 
transfused patients was INR corrected after the FFP 
transfusion. This result confirms some other 
observations that the standard recommended dose of 
FFP fails to correct coagulation deficit in a majority of 
critically ill patients [13]. According to the studies, INR 
level is a poor predictor of subsequent bleeding in the 
critically ill patients, and in lots of patients, specific 
factor concentrations remain adequate to prevent 
microvascular bleeding [13]. A significant number of 
patients with coagulopathy received FFP transfusion 
without any demonstrated efficacy [5] [13]. Other 
sources, such as Abdel-Wahab OI et al., have 
concluded that whatever the volume of transfused 
plasma, plasma transfusions did not correct moderate 
coagulopathy [8]. In another observational study by 
Holland et al., authors showed that plasma 
transfusions did not correct INR levels <2.0–2.5 [9]. 
So, the current practice of FFP transfusion is likely to 
expose the patients to transfusion risks with little or no 
documented benefit. During recent years new 
guidelines have been promoted to educate the 
hospital personnel [10]. 
It is important to emphasise that 
recommendations in the current guidelines are based 
on expert opinion, as no randomised studies are 
available. In the current study, FFP was commonly 
used before an invasive procedure. Although there is 
a little evidence for the effectiveness of the 
prophylactic use of FFP, previous studies have shown 
that invasive procedures can be done safely in 
patients with disorders of hemostasis by skilled 
physicians who frequently perform these procedures 
[5] [11]. Although some published guidelines currently 
define an invasive procedure as one of the indications 
for FFP transfusion, our data do not support this 
practice for the common critical care procedures [12]. 
We also found the considerable use of FFP in patients 
who had recent bleeding but no active ongoing 
bleeding. FFP transfusion was primarily aimed for 
reversal of warfarin effect. However, the latest British 
Society for Hematology guidelines clearly states that 
FFP should not be transfused for the reversal of 
warfarin anticoagulation when there is no evidence of 
severe active bleeding [10]. Previous studies also 
suggested that FFP may not be particularly effective 
in replacing coagulation factors [13]. In our study, FFP 
transfusion remained significantly associated with the 
development of acute lung injury (p = 0.05). However, 
the present study has some circumstantial limitations, 
and the reported data need replication.  
In conclusion, plasma transfusion is a 
common treatment for critical care patients, and it may 
bring benefits for those who are massively bleeding. 
In our study, we concluded that FFP transfusion in 
critically ill medical patients with coagulopathy but 
without active bleeding. Plasma transfusions may be 
associated with worse outcomes, so the risk-benefit 
ratio of liberal FFP transfusion strategy may not be 
favourable.  
Therefore, the decision to proceed with 
plasma transfusion must be based on individualised 
indications, and most physicians suggest plasma 
transfusions according to their own experiences while 
balancing the risks and benefits. Unfortunately, no 
randomised, controlled trial has yet decided the 
appropriate plasma transfusion threshold. Freshly 
frozen plasma transfusions are often unnecessarily 
indicated because of the inadequate correction of the 
deficiencies of coagulation factors and so comparing a 
liberal FFP transfusion strategy vs a restrictive one 
are required other clinical trials to asses which one is 
the best to perform to avoid the unnecessarily 
exposures to the ICU patients. 
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